Kiyoshi Ariizumi, Ph.D. Titles and Appointments Professor School Medical School Department Dermatology Graduate Programs Cancer Biology, Immunology Biography We are interested in the mechanisms of a continuously changing equilibrium where the immune system tries to recognize and destroy cancer cells, while cancer cells accordingly acquire genetic alterations to evade immune surveillance. Our goals are to define molecular mechanisms through which cancers acquire resistance to immunotherapy; create new modalities to change the equilibrium towards immune dominance; and develop new approaches for functional precision cancer medicine. Education Graduate School University of Tokyo (1985) Research Interest Acquired resistance to immune checkpoint inhibitors Cancer-induced alterations of carbohydrate metabolism Functional precision cancer medicine Regulation of tumor angiogenesis Publications Acquired resistance to immune checkpoint therapy is caused by glycoprotein non-metastatic melanoma protein B signal cascade Chung J, Ramani V, Guo L, Popat V, Cruz PD, Xu L, Hammers H, Ariizumi K Communications Medicine 2025 Dec 5 Phase II Trial of Sipuleucel-T and Stereotactic Ablative Body Radiation for Patients with Metastatic Castrate-Resistant Prostate Cancer Hannan R, Dohopolski MJ, Pop LM, Mannala S, Watumull L, Womack KB, Gao A, Garant A, Arriaga YE, Bowman I, Chung J, Wang J, Ariizumi K, Ahn C, Timmerman R, Courtney K Biomedicines 2022 Jun 10 Soluble DC-HIL/Gpnmb Modulates T-Lymphocyte Extravasation to Inflamed Skin Ramani V, Chung JS, Ariizumi K, Cruz PD Journal of Investigative Dermatology 2022 May 142 1372-1380.e5 DC-HIL/GpNMB is a negative regulator of tumor response to immune checkpoint inhibitors Chung JS, Ramani V, Kobayashi M, Fattah F, Popat V, Zhang S, Cruz PD, Gerber DE, Ariizumi K Clinical Cancer Research 2020 Mar 26 1449-1459 Expansion of Myeloid-Derived Suppressor Cells in the Peripheral Blood and Lesional Skin of Cutaneous Lupus Patients Florez-Pollack S, Tseng Lc, Kobayashi M, Hosler GA, Ariizumi K, Chong B Journal of Investigative Dermatology 2019 Feb 139 478-481 Blocking monocytic myeloid-derived suppressor cell function via anti-DC-HIL/GpNMB antibody restores the in vitro integrity of T cells from cancer patients Kobayashi M, Chung JS, Beg M, Arriaga Y, Verma U, Courtney K, Mansour J, Haley B, Khan S, Horiuchi Y, Ramani V, Harker D, Gopal P, Araghizadeh F, Cruz PD, Ariizumi K Clinical Cancer Research 2019 Jan 25 828-838 NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation Brosseau JP, Liao Ph.D. CP, Wang Y, Ramani V, Vandergriff TW, Lee M, Patel A, Ariizumi K, Le LQ Nature communications 2018 Dec 9 Melanoma-Derived Soluble DC-HIL/GPNMB Promotes Metastasis by Excluding T-Lymphocytes from the Pre-Metastatic Niches Ramani V, Teshima T, Tamura K, Chung JS, Kobayashi M, Cruz PD, Ariizumi K Journal of Investigative Dermatology 2018 Nov 138 2443-2451 Myeloid-Derived Suppressor Cells in Psoriasis Are an Expanded Population Exhibiting Diverse T-Cell–Suppressor Mechanisms Cao LY, Chung JS, Teshima T, Feigenbaum L, Cruz PD, Jacobe H, Chong B, Ariizumi K Journal of Investigative Dermatology 2016 Sep 136 1801-1810 DC-HIL-expressing myelomonocytic cells are critical promoters of melanoma growth Chung JS, Tamura K, Cruz PD, Ariizumi K Journal of Investigative Dermatology 2014 Nov 134 2784-2794 Results 1-10 of 80 1 2 3 4 5 Next Last Honors & Awards Research career Development AwardAwarded by the Dermatology Foundation (1994) Henry Christian Memorial AwardAwarded by the American Federation for Clinical Research (1993) Professional Associations/Affiliations American Association for Cancer Research (2015) Society of Investigative Dermatology (1994)
